Biomarkers for Cancer Early Detection and Survival Prediction Study

Led by Dr. Roberts, our lab is studying biomarkers for early detection of hepatocellular carcinoma and survival prediction.

Our cancer biomarkers studies include:

Hepatocellular Carcinoma Early Detection Strategy Study

The purpose of this study is to evaluate the usefulness of new biomarkers for early diagnosis of liver cancer among people with cirrhosis using routine surveillance for hepatocellular carcinoma for up to four years.

Bile Biomarkers for Detecting IgG4-Related Sclerosing Cholangitis

IgG4-sclerosing cholangitis (IgG4-SC) can be difficult to distinguish from primary sclerosing cholangitis and cholangiocarcinoma.

Dr. Roberts and his research team are evaluating the sensitivity and specificity of bile IgG-4 level to differentiate benign biliary tract stricture from cholangiocarcinoma in patients with IgG4-SC.

Detection of Actionable or Predictive Tumor DNA Mutations in Peripheral Blood From Patients With Hepatocellular Carcinoma

The lab's research team is prospectively collecting peripheral blood samples for analysis of DNA mutation and hypermethylation to differentiate patients with cirrhosis with and without hepatocellular carcinoma.

BALAD Score as a Survival Outcome Predictor for Patients With Hepatocellular Carcinoma

This project in the Hepatobiliary Cancer Lab aims to use a combination of biomarkers that includes serum bilirubin, albumin, AFP, AFP-3 and DCP to predict outcomes of patients with hepatocellular carcinoma and to validate the use of the BALAD score in North America.